Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore in net profit, compared to ₹166 crore in the same period last year. This sharp rise is being attributed to robust hospital performance, diagnostics expansion, and tighter cost controls.
According to the financials released, Fortis clocked in revenue of ₹1,856 crore for the April–June quarter, registering an 8.6% year-on-year growth. The hospital business contributed ₹1,456 crore to the total revenue—marking a significant 12.8% rise.
The diagnostics segment, however, saw a dip. Revenues from this vertical fell 6.4% to ₹399 crore, primarily due to lower COVID-related testing compared to last year. Despite this, the company’s overall profitability remained strong.
EBITDA Shows Strong Momentum
The company’s EBITDA (Earnings Before Interest, Tax, Depreciation and Amortisation) rose by 10.4% to ₹365 crore in Q1. The EBITDA margin remained stable at 19.7%, indicating efficient operational performance and cost discipline.
Fortis attributed this growth to a mix of high-end procedures, strong occupancy rates in its flagship hospitals, and better case mix. International patient inflow has also returned to pre-COVID levels, contributing to better margins.
Chairman’s Note
Fortis Healthcare Chairman Ravi Rajagopal stated,
> “We are witnessing a strong momentum in our hospital vertical. Our expansion strategy is on track, and we continue to invest in technology and infrastructure upgrades to deliver world-class care.”
The company is actively pursuing brownfield expansions across several metro and Tier-II cities. Plans include bed additions and new centres under the diagnostics vertical.
Future Outlook
Analysts see Fortis’ Q1 results as a strong indicator of sustained recovery and profitability. With international travel normalizing and medical tourism resuming, the outlook remains bullish.
The company is also optimistic about increased demand for elective surgeries and specialized treatments. Fortis plans to scale its high-end offerings such as oncology, transplants, and robotic surgeries.
